Main Serological Markers of Systemic Rheumatic Autoimmune Diseases

Weuley Pereira de Souza, Cristiene Costa Carneiro, Xisto Sena Passos

Resumo


Systemic rheumatic autoimmune diseases are complex chronic inflammatory disorders, generally with impairment of joins and systemic manifestations. This study is a literature review about the main serologic markers used in the screening of these illnesses. The assessment of the presence of autoantibodies is an essential component in the initial diagnosis of autoimmune diseases. The production of these antibodies occurs via humoral immune response against self-antigens, and these antibodies are often present in the serum of patients diagnosed with autoimmune illness. Each antibody has a different function and specificity and this is directly associated with clinic manifestations and disease course. The main markers detected in rheumatology have antinuclear, prothrombotic and inflammatory action; therefore depending on the complexity of the illness, several markers can be identified, assisting both in diagnosis and prognosis disease.

----------------------------------------------------------------------------------

Principais marcadores sorológicos de doenças reumáticas autoimunes sistêmicas

Doenças reumáticas autoimunes sistêmicas são doenças inflamatórias crônicas, complexas, geralmente com comprometimento das articulações acompanhado de manifestações sistêmicas. O presente estudo trata-se de uma revisão bibliográfica sobre os principais marcadores sorológicos utilizados no rastreio dessas doenças. A avaliação da presença de autoanticorpos constitui parte essencial no diagnóstico inicial de doenças autoimunes. A produção desses anticorpos ocorre através de resposta imune humoral contra antígenos próprios, e estão frequentemente presentes no soro de pacientes diagnosticados com doença autoimune. Cada anticorpo tem função, e especificidade diferentes, e isso influencia diretamente na manifestação e curso da doença. Os principais marcadores detectados em reumatologia têm ação antinuclear, pró-trombótica e inflamatória, por isso, dependendo da complexidade da doença, vários marcadores podem ser encontrados, auxiliando tanto no diagnóstico quanto no prognóstico.


----------------------------------------------------------------------------------

■ Text in Portuguese

Palavras-chave


Autoantibodies; Antinuclear antibodies; Serologic markers; Autoimmune rheumatic diseases; Autoanticorpos; Anticorpos antinucleares; Marcadores sorológicos; Doenças reumáticas autoimunes.

Texto completo:

PDF

Referências


SOUZA A. W. S. DE, JUNIOR D. M., ARAÚJO J. A. P, CATELAN T. T. T., CRUVINEL W. DE M., ANDRADE L. E. C. & SILVA N. P. 2010. Sistema imunitário: parte III, O delicado equilíbrio do sistema imunológico entre os pólos de tolerância e autoimunidade. Revista Brasileira de Reumatologia 50:665–679.

KEARNEY J. F. 1994. Formation of autoantibodies, including anti-cytokine antibodies, is a hallmark of the immune response of early B cells. Journal of Interferon Research 14:151–152.

POLLARD K. M., HULTMAN P. & KONO D. H. 2010. Toxicology of Autoimmune Diseases. Chemical Research in Toxicology 23:455–466.

ANAYA J., SHOENFELD Y., BUTTGEREIT F. & GONZALEZ-GAY M. A. 2014. Autoimmune Rheumatic Diseases. BioMed Research International 1–3.

VASSILOPOULOS D. & HOFFMAN G. S. 1999. Clinical utility of testing for antineutrophil cytoplasmic antibodies. Clinical and Diagnostic Laboratory Immunology 6:645–651.

HIMOTO T. & NISHIOKA M. 2013. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Autoimmunity Highlights 4:39–53.

DELLAVANCE A., JÚNIOR A. G., CINTRA A. F. U., XIMENES A. C., NUCCITELLI B., TALIBERTI B. H., MOREIRA C., MÜHLEN C. A. V., BICHARA C. D., SANTOS C. H. R., YANO C. M., MANGUEIRA C. L. P., CARVALHO D. G., BONFÁ E. S. D. O., DOI E. M., GUIMARAES F. N. C., ARAÚJO F. I., MUNDIM H. M., REGO J., VIEIRA L. E. A., POLI L., ANDRADE L. E. C., CALLADO M. R., MESQUITA M. M., SUGIYAMA M., SLHESSARENKO M., SILVA N. A., CARBALLO O. G., LESER P. G., FRANCESCANTONIO P. L. C., JARACH R., XAVIER R. M., LEVY R. A., NEVES S. P. F., CRUVINEL W. DE M. & SANTOS W. S. 2003. II Consenso Brasileiro de Fator Antinuclear em Células HEp-2, Definições para a padronização da pesquisa de autoanticorpos contra constituintes do núcleo (FAN HEp-2), nucléolo, citoplasma e aparelho mitótico e suas associações clínicas. Revista Brasileira de Reumatologia 43:129–140.

DUARTE A. A. 2005. Fator antinúcleo na dermatologia. Anais Brasileiros de Dermatologia 80:387–394.

SOMERS E. C., GANSER M. A., WARREN J. S., BASU N., WANG L. & ZICK S. M. 2015. Mercury Exposure and Antinuclear Antibodies among Females of Reproductive Age in the United States: NHANES. Environmental Health Perspectives 123:792–798.

LI Q., KARP D. R., QUAN J., BRANCH V. K., ZHOU J., LIAN Y., CHONG B. F., WAKELAND E. K. & OLSEN N. J. 2011. Risk factors for ANA positivity in healthy persons. Arthritis Research & Therapy 13:1–11.

HIRA-KAZAL R., SHEA-SIMONDS P., PEACOCK J. L. & MAHER J. 2014. How should a district general hospital immunology service screen for anti-nuclear antibodies? An “in-the-field” audit. Clinical and Experimental Immunology 180:52–57.

DAMOISEAUX J., MÜHLEN C. A. V., TORRE I.G. LA, CARBALLO O. G., CRUVINEL W. DE M., FRANCESCANTONIO P. L. C., FRITZLER M. J., HEROLD M., MIMORI T., SATOH M., ANDRADE L. E. C., CHAN E. K. L. & CONRAD K. 2016. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Autoimmunity Highlights 7:1–8.

DELLAVANCE A., JÚNIOR A. G., NUCCITELLI B., TALIBERTI B. H., MÜHLEN C. A. V., BICHARA C. D. A., SANTOS C. H. R., BUENO C., YANO C. M., MANGUEIRA C. L. P., CARVALHO D. G., CARDOSO E., BONFÁ E., ARAÚJO F. I., RASSI G. G., MUNDIM H. M., BENDET I., REGO J., VIEIRA L. M. E. A., ANDRADE L. E. C., BARBOSA M. O. F., SUGIYAMA M., SANTIAGO M. B., SLHESSARENKO N., SILVA N. A., FRANCESCANTONIO P. L. C., JARACH R., SUDA R., LEVY R. A., SAMPAIO S. O., NEVES S. P. F., CRUVINEL W. DE M., SANTOS W. S. & NÓBREGA Y. K. DE M. 2009. 3o Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2 (FAN): Recomendações para padronização do ensaio de pesquisa de autoanticorpos em células HEp-2, controle de qualidade e associações clínicas. Revista Brasileira de Reumatologia 249:89–98.

MARTINS T. B., BURLINGAME R., MU C. A. V., JASKOWSKI T. D., LITWIN C. M. & HILL H. R. 2004. Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clinical and Diagnostic Laboratory Immunology 11:1054–1059.

ORTON S. M., PEACE-BREWER A., SCHMITZ J. L., FREEMAN K., MILLER W. C. & FOLDS J. D. 2004. Practical evaluation of methods for detection and specificity of autoantibodies to extractable nuclear antigens. Clinical and Diagnostic Laboratory Immunology 11:297–301.

SÁNCHEZ-GUERRERO J., LEW R. A., FOSSEL A. H. & SCHUR P. H. 1996. Utility of anti-Sm, anti-RNP, anti-Ro/SSA, and anti-La/SSB (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis and Rheumatism 39:1055–1061.

YOSHIMI R., UEDA A., OZATO K. & ISHIGATSUBO Y. 2012. Clinical and pathological roles of Ro/SSA autoantibody system. Clinical and Developmental Immunology 1–12.

TOULOUPI E., ROUTSIAS J. G. & TZIOUFAS A. G. 2005. Cross-recognition between histones and La/SSB may account for anti-DNA reactivity in SLE patients. Clinical and Experimental Immunology 142:172–179.

ARROYO-ÁVILA M., SANTIAGO-CASAS Y., JUNIOR G. M., CANTOR R. S., PETRI M., RAMSEY-GOLDMAN R. REVEILLE J. D., KIMBERLY R. P., ALARCÓN G. S., VILÁ L. M. & BROWN E. E. 2015. Clinical associations of anti-Smith antibodies in profile: a multi-ethnic lupus cohort. Clinical Rheumatology 34:1217–1223.

CARPINTERO M. F., MARTINEZ L., FERNANDEZ I., ROMERO A. C. G., MEJIA C., ZANG Y., HOFFMAN R. W. & GREIDINGER E. L. et al. 2015. Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus 24:1057–1066.

WANG X., STEARNS N. A., LI X. & PISETSKY D. S. 2014. The effect of polyamines on the binding of anti-DNA antibodies for patients with SLE and normal human subjects. Clinical Immunology 153:94–103.

PAVLOVIC M., KATS A., CAVALLO M., CHEN R., HARTMANN J. X. & SHOENFELD Y. 2010. Pathogenic and Epiphenomenal Anti-DNA Antibodies in SLE. Autoimmune Diseases 1–18.

SWANSON P. C., ACKROYD C. & GLICK G. D. 1996. Ligand Recognition by Anti-DNA Autoantibodies. Affinity, Specificity, and Mode of Binding. Biochemistry 35:1624–1633.

KRISHNAN M. R., WANG C. & MARION T. N. 2012. Anti-DNA auto-antibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney International 82:184–192.

INGEGNOLI F., CASTELLI R. & GUALTIEROTTI R. 2013. Rheumatoid Factors: Clinical Applications. Disease Markers 35:727–734.

MOTA L. M. H. DA, NETO L. L. DOS S., BURLINGAME R. & LAURINDO I. M. M. 2009. Comportamento distinto dos sorotipos do fator reumatoide em avaliação seriada de pacientes com artrite reumatoide inicial. Revista Brasileira de Reumatologia 49:223–235.

ROOS K., MARTINSSON K., ZIEGELASCH M., SOMMARIN Y., SVÄRD A., SKOGH T. & KASTBOM ALF. 2016. Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking. Arthritis Research & Therapy 18:1–9.

KROOT E. J., JONG B. A. DE, LEEUWEN M. A. V., SWINKELS H., HOOGEN F. H. V. D., HOF M. V., PUTTE L. B. V., RIJSWIJK M. H. V., VENROOIJ M. J. V. & RIEL P. L. V. 2000. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism 43:1831–1835.

ALETAHA D., ALASTI F. & SMOLEN J. S. 2015. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Research & Therapy 17:229.

POLLOCK W., CLARKE K., GALLAGHER K., HALL J., LUCKHURST E., MCEVOY R., MELNY J., NEIL J., NIKOLOUTSOPOULOS A., THOMPSON T., TREVISIN M. & SAVIGE J. 2002. Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate. Journal of Clinical Pathology 55:680–683.

SAVIGE J., DAVIES D., FALK R. J., JENNETTE J. C. & WIIK A. 2000. Antineutrophil cytoplasmic antibodies and associated diseases : A review of the clinical and laboratory features. Kidney International 57:846–862.

SCHULTE-PELKUM J., RADICE A., NORMAN G. L., LPEZ HOYOS M., LAKOS G., BUCHNER C., MUSSET L., MIYARA M., STINTON L. & MAHLER M. 2014. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. Journal of Immunology Research 1-12.

CSERNOK E. & HOLLE J. U. 2010. Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA – evidence-based immunology? Autoimmunity Highlights 1:39–43.

WILSON W. A., GHARAVI A. E., KOIKE T., LOCKSHIN M. D., BRANCH D. W., PIETTE J., BREY R., DERKSEN R., HARRIS E. N., HUGHES G. R. V., TRIPLETT D. A. & KHAMASHTA M. A. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis and Rheumatism 42:1309–1311.

FISCHER M. J., RAUCH J. & LEVINE J. S. 2007. The Antiphospholipid Syndrome. Seminars in Nephrology 27:35–46.

WILLIS R. & PIERANGELI S. S. 2011. Pathophysiology of the antiphospholipid antibody syndrome. Autoimmunity Highlights 2:35–52.

TRIPLETT D. A. 2002. Antiphospholipid Antibodies. Archive of Pathology and Laboratory Medicine 126:1424–1429.

HORSTMAN L. L., JY W., BIDOT C. J., AHN Y. S., KELLEY R. E., ZIVADINOV R. MAGHZI A. H., ETEMADIFAR M., MOUSAVI S. A. & MINAGAR A. 2009. Antiphospholipid antibodies: paradigm in transition. Journal of Neuroinflammation 6:1–21.

EDIRIWICKREMA L. S. & ZAHEER W. 2011. Diffuse large cell Lymphoma presenting as a sacral mass and lupus anticoagulant. Yale Journal of Biology and Medicine 84:433–438.

BOWIE E. J. W., JUNIOR J. H. T., PASCUZZI C. A. & JUNIOR C. A. O. 1963. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. Translational Research 62:416–430.

ORTEL T. L. 2012. Antiphospholipid syndrome laboratory testing and diagnostic strategies. American Journal of Hematology 87:1–17.

CHAO Y., CHANG W., TING H., CHAO W. & HSU Y. H. 2014. Cell Cycle Arrest and Cell Survival Induce Reverse Trends of Cardiolipin Remodeling. PLoS One 9:1–19.

SANTAMARIA J. R, MANDELLI F. L, BADZIAK D., CAVALIN L. C., DE BARROS M. F. & SATO M. S. 2005. Síndrome antifosfolípide. Anais Brasileiros de Dermatologia 80:225–239.

ANZAI K., NAGAFUCHI S., NIHO Y., KIKUCHI M. & ONO J. 1988. β2-Glycoprotein I-dependent and -independent anticardiolipin antibody in non-obese diabetic (NOD) mice. Clinical and Experimental Immunology 111:173–180.

SPECKER C. 2007. Antiphospholipidsyndrom. Zeitschrift für Rheumatologie. 66:41–53.

ARAD A., PROULLE V., FURIE R A., FURIE B. C. & FURIE B. 2011. β(2)-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 117:3453–3459.

RANZOLIN A., LOTTERMAN A., BOHN J., ALBERTO C., MÜHLEN V. & LUIZ H. 2004. Anticorpos contra Beta2-Glicoproteína I, autoimunidade e aterosclerose. Revista Brasileira de Reumatologia 44:139–149.

CARMONA-FERNANDES D., SANTOS M. J., CANHÃO H. & FONSECA J. E. 2013. Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Medicine 11:1–8.

MARIN G. G., CARDIEL M. H., CORNEJO H. & VIVEROS M. E. 2009. Prevalence of Antinuclear Antibodies in 3 Groups of Healthy Individuals: Blood Donors, Hospital Personnel, and Relatives of Patients With Autoimmune Diseases. Journal of Clinical Rheumatology 15:325–329.

CARCAMO W. C., SATOH M., KASAHARA H., TERADA N., HAMAZAKI T., CHAN J. Y. F., YAO B., TAMAYO S., COVINI G., MÜHLEN C. A V. & CHAN E. K. L. 2011. Induction of Cytoplasmic Rods and Rings Structures by Inhibition of the CTP and GTP Synthetic Pathway in Mammalian Cells. PLoS One 6:1–12.

MOLAZADEH M., KARIMZADEH H. & AZIZI M. R. 2014. Prevalence and clinical significance of antinuclear antibodies in Iranian women with unexplained recurrent miscarriage. Iranian Journal of Reproductive Medicine 12:221–226.

RAND J. H., WU X. X., QUINN A. S. & TAATJES D. J. 2008. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 17:922–930.

RAND J. H., WU X., QUINN A. S., CHEN P. P., MCCRAE K. R., BOVILL E. G. & TAATJES D. J. 2003. Human Monoclonal Antiphospholipid Antibodies Disrupt the Annexin A5 Anticoagulant Crystal Shield on Phospholipid Bilayers Evidence from Atomic Force Microscopy and Functional. American Journal of Pathology 163:1193–1200.

RAND J. H., WU X., ANDREE H. A. M., ROSS J. B. A., RUSINOVA E., GASCON-LEMA M. G., CALANDRI C. & HARPEL P. C. 1998. Antiphospholipid Antibodies Accelerate Plasma Coagulation by Inhibiting Annexin-V Binding to Phospholipids: A “‘Lupus Procoagulant’” Phenomenon. Blood 92:1652–1660.

CHUNG C. H. & PARK C. Y. 2008. Lupus anticoagulant-hypoprothrombinemia in healthy adult. The Korean Journal of Internal Medicine 23:149–151.

CAMPOS M. M. & SANTOS I. R. 2011. Síndrome De Hipoprotrombinémia - Anticoagulante Lúpico. Acta Médica Portuguesa 24:611–616.

RAPAPORT S. I., AMES S. B. & DUVALL B. J. 1959. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 15:212–227.




DOI: http://dx.doi.org/10.18224/evs.v0i0.5314

Rodapé - Educativa
 

Este obra está licenciada com uma Licença Creative Commons - Atribuição Sem Derivações 4.0 CC BY-NC-ND


EVS | Pontifícia Universidade Católica de Goiás | e-ISSN 1983-781X | Qualis B3

Visitantes - (05/09/2017 - 21/10/2019)
País Usuários
Brasil 51.961
Estados Unidos 1.284
Portugal 818
França 246
Moçambique 238
Angola 171
Reino Unido 61
México 61
Espanha 60

Fonte: Google Analytics.